about
PEGylated Adenoviruses: From Mice to MonkeysPharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim.Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model.Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation.Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma.Pharmacokinetic consequences of pegylation.First-line treatment of acute lymphoblastic leukemia with pegasparaginase.Designing PEGylated therapeutic molecules: advantages in ADMET properties.L-asparaginase: an effective agent in the treatment of acute lymphoblastic leukemia.Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase.
P2860
Q24635276-0A3759EB-EA0D-459B-8E58-4DF2205DEC63Q33336647-A05E37D4-0031-4C77-AA66-1276D2E337F3Q33901283-53CE84DB-7BCB-4715-AC72-31C7164902BCQ34747443-D994CE59-9322-409C-89DD-433C073E397DQ35025684-E5F1592B-1E25-4189-8392-15F732B97DC5Q36604526-91237DB6-6EB9-4CED-9E56-5C54587C2268Q37586935-DED4D1DA-1FA9-498C-8A3D-48849253DD9AQ38089879-38D59B77-32CD-451B-AA2C-97EA7576F463Q38105626-E79BF0FB-C7DF-467B-905E-76B33622138DQ53585030-0E4A7725-5C57-49C5-B1DF-B8A3C93C93F3
P2860
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Pegaspargase: an alternative?
@en
type
label
Pegaspargase: an alternative?
@en
prefLabel
Pegaspargase: an alternative?
@en
P2860
P1476
Pegaspargase: an alternative?
@en
P2093
P2860
P304
P356
10.1177/106002809703100517
P407
P577
1997-05-01T00:00:00Z